Indeed, it has been suggested that the strong inhibitory effect on tumor growth displayed by MIA antagonists could be attributed to either the downregulation of tumoral GHRH-R and SV1 levels or the conformational changes of the receptors, which would lead to different signaling responses [17,18,21,28,29]. Here, GHRHR is linked to neoplasm.